AVTX Projected Dividend Yield

Com Par $0.001/Avalo Therapeutics Inc ( NASDAQ : AVTX )

Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. Co.'s clinical-stage pipeline include: AVTX-002, which is a fully human monoclonal antibody, directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator, a receptor expressed by T lymphocytes) being developed for the treatment of non-eosinophilic asthma; AVTX-008, which is a fully human B and T Lymphocyte Attenuator agonist fusion protein; and AVTX-803, which is a fucose replacement for leukocyte adhesion deficiency type II.

20 YEAR PERFORMANCE RESULTS